Erratum to “CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease”

doi:10.1002/ctm2.70434

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (8) : e70434 DOI: 10.1002/ctm2.70434

CORRECTION

Erratum to “CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease”

Author information +

History +

PDF

Cite this article

Download citation ▾

null. Erratum to “CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease”. Clinical and Translational Medicine, 2025, 15(8): e70434 DOI:10.1002/ctm2.70434

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.